A Phase 3 interventional study of etoricoxib (MK0663) 120 mg and Comparator: Placebo in Acute Pain Following a Total Abdominal Hysterectomy, sponsored by Organon and Co. Completed. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-09.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the efficacy and safety of etoricoxib compared to placebo in the treatment of postoperative pain associated with total abdominal hysterectomy.
1,075 studies on the registry are indexed under Acute Pain; 167 are open to participants now.
This study's enrollment of 430 is above the median of 86 across 903 interventional studies indexed under Acute Pain.
Browse Acute Pain studies →Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
etoricoxib (MK0663) 120 mg (2 60 mg tablets) and 1 placebo tablet once daily on Days 1-5. Total treatment is 5 days.
Drug: etoricoxib (MK0663) 120 mg
etoricoxib (MK0663) 90 mg tablet and 2 placebo tablets once daily on Days 1-5. Total treatment is 5 days.
Drug: etoricoxib (MK0663) 90 mg
Placebo- 3 tablets once daily
Drug: Comparator: Placebo
120 mg of etoricoxib (MK0663) for a total of 5 days
Also known as: Arcoxia
Placebo tablets once daily on Days 1-5. Total treatment is 5 days.
90 mg of etoricoxib (MK0663) for a total of 5 days
Average Pain Intensity at Rest Over Days 1 to 3
Pain intensity at rest was measured on a 0- to 10-point scale: 0=no pain, to 10=pain as bad as you can imagine.
Time frame: 3 Days
Average Total Daily Dose of Morphine Over Days 1 to 3
Time frame: 3 days
Average Elicited Pain Upon Sitting Over Days 1 to 3
Elicited pain upon sitting was measured on a 0- to 10-point scale: 0=no pain, to 10=pain as bad as you can imagine.
Time frame: 3 days
| Milestone | Etoricoxib 120 mg | Etoricoxib 90 mg | Placebo |
|---|---|---|---|
| Started | 144 | 142 | 144 |
| Completed | 139 | 134 | 138 |
| Not completed | 5 | 8 | 6 |
| Withdrew: Adverse event | 1 | 3 | 4 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Physician decision | 2 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 2 | 2 | 0 |
Pain intensity at rest was measured on a 0- to 10-point scale: 0=no pain, to 10=pain as bad as you can imagine.
| Score on a scale | Etoricoxib 120 mg | Etoricoxib 90 mg | Placebo |
|---|---|---|---|
| Average Pain Intensity at Rest Over Days 1 to 3 | 2.40 ± 0.15 | 2.46 ± 0.15 | 3.26 ± 0.15 |
| milligrams (mg) | Etoricoxib 120 mg | Etoricoxib 90 mg | Placebo |
|---|---|---|---|
| Average Total Daily Dose of Morphine Over Days 1 to 3 | 5.37 ± 0.08 | 5.46 ± 0.08 | 7.75 ± 0.08 |
Elicited pain upon sitting was measured on a 0- to 10-point scale: 0=no pain, to 10=pain as bad as you can imagine.
| Score on a scale | Etoricoxib 120 mg | Etoricoxib 90 mg | Placebo |
|---|---|---|---|
| Average Elicited Pain Upon Sitting Over Days 1 to 3 | 3.58 ± 0.17 | 3.80 ± 0.17 | 4.71 ± 0.17 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Etoricoxib 120 mg | — | 5/144 (3.5%) | 60/144 (41.7%) |
| Etoricoxib 90 mg | — | 5/142 (3.5%) | 51/142 (35.9%) |
| Placebo | — | 10/144 (6.9%) | 65/144 (45.1%) |
| Event | Etoricoxib 120 mg | Etoricoxib 90 mg | Placebo |
|---|---|---|---|
| FaecalomaGastrointestinal disorders | 0/144 | 1/142 | 0/144 |
| Operative haemorrhageInjury, poisoning and procedural complications | 0/144 | 1/142 | 0/144 |
| HypokalaemiaMetabolism and nutrition disorders | 0/144 | 1/142 | 0/144 |
| Uterine cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/144 | 1/142 | 0/144 |
| Vaginal haemorrhageReproductive system and breast disorders | 0/144 | 1/142 | 0/144 |
| Respiratory depressionRespiratory, thoracic and mediastinal disorders | 0/144 | 1/142 | 0/144 |
| Abdominal painGastrointestinal disorders | 1/144 | 0/142 | 0/144 |
| Small intestinal obstructionGastrointestinal disorders | 1/144 | 0/142 | 0/144 |
| CellulitisInfections and infestations | 0/144 | 0/142 | 1/144 |
| Postoperative wound infectionInfections and infestations | 0/144 | 0/142 | 1/144 |
| Event | Etoricoxib 120 mg | Etoricoxib 90 mg | Placebo |
|---|---|---|---|
| NauseaGastrointestinal disorders | 40/144 | 31/142 | 38/144 |
| PyrexiaGeneral disorders | 7/144 | 4/142 | 24/144 |
| ConstipationGastrointestinal disorders | 16/144 | 12/142 | 18/144 |
| FlatulenceGastrointestinal disorders | 7/144 | 14/142 | 12/144 |
| DizzinessNervous system disorders | 12/144 | 9/142 | 14/144 |
| HeadacheNervous system disorders | 9/144 | 8/142 | 14/144 |
| PruritusSkin and subcutaneous tissue disorders | 5/144 | 13/142 | 6/144 |
| VomitingGastrointestinal disorders | 10/144 | 7/142 | 10/144 |
| Age, Continuous(years) | Etoricoxib 120 mg | Etoricoxib 90 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 46.3 ± 6.9 | 47.0 ± 7.2 | 45.7 ± 7.0 | 46.3 ± 7.0 |
| Sex: Female, Male(Participants) | Etoricoxib 120 mg | Etoricoxib 90 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 144 | 142 | 144 | 430 |
| Male | 0 | 0 | 0 | 0 |
No study locations are listed for this record.
The record gives a start of Oct 2008, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2011, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Etoricoxib